191 related articles for article (PubMed ID: 29783159)
1. Fas/FasL interaction mediates imbalanced cytokine/cytotoxicity responses of iNKT cells against Jurkat cells.
Dou R; Hong Z; Tan X; Hu F; Ding Y; Wang W; Liang Z; Zhong R; Wu X; Weng X
Mol Immunol; 2018 Jul; 99():145-153. PubMed ID: 29783159
[TBL] [Abstract][Full Text] [Related]
2. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
3. Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency.
Wingender G; Krebs P; Beutler B; Kronenberg M
J Immunol; 2010 Sep; 185(5):2721-9. PubMed ID: 20660713
[TBL] [Abstract][Full Text] [Related]
4. Elevated Hepatic CD1d Levels Coincide with Invariant NKT Cell Defects in Chronic Hepatitis B Virus Infection.
Tan X; Ding Y; Zhu P; Dou R; Liang Z; Yang D; Huang Z; Wang W; Wu X; Weng X
J Immunol; 2018 May; 200(10):3530-3538. PubMed ID: 29643189
[TBL] [Abstract][Full Text] [Related]
5. Human CD4+ invariant NKT cells are involved in antibacterial immunity against Brucella suis through CD1d-dependent but CD4-independent mechanisms.
Bessoles S; Dudal S; Besra GS; Sanchez F; Lafont V
Eur J Immunol; 2009 Apr; 39(4):1025-35. PubMed ID: 19266487
[TBL] [Abstract][Full Text] [Related]
6. Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide.
Croudace JE; Curbishley SM; Mura M; Willcox CR; Illarionov PA; Besra GS; Adams DH; Lammas DA
BMC Immunol; 2008 Dec; 9():71. PubMed ID: 19055753
[TBL] [Abstract][Full Text] [Related]
7. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
8. Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors.
Guo T; Chamoto K; Nakatsugawa M; Ochi T; Yamashita Y; Anczurowski M; Butler MO; Hirano N
PLoS One; 2016; 11(5):e0156114. PubMed ID: 27213277
[TBL] [Abstract][Full Text] [Related]
9. The tumor antigen N-glycolyl-GM3 is a human CD1d ligand capable of mediating B cell and natural killer T cell interaction.
Gentilini MV; Pérez ME; Fernández PM; Fainboim L; Arana E
Cancer Immunol Immunother; 2016 May; 65(5):551-62. PubMed ID: 26969612
[TBL] [Abstract][Full Text] [Related]
10. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
11. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
12. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
[TBL] [Abstract][Full Text] [Related]
13. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
Yang G; Artiaga BL; Lewis ST; Driver JP
Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
[TBL] [Abstract][Full Text] [Related]
14. Circulating CD56dim natural killer cells and CD56+ T cells that produce interferon-γ or interleukin-10 are expanded in asymptomatic, E antigen-negative patients with persistent hepatitis B virus infection.
Conroy MJ; Mac Nicholas R; Grealy R; Taylor M; Otegbayo JA; O'Dea S; Mulcahy F; Ryan T; Norris S; Doherty DG
J Viral Hepat; 2015 Mar; 22(3):335-45. PubMed ID: 25186004
[TBL] [Abstract][Full Text] [Related]
15. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.
Xu T; Sun BC; Li Q; Hao XS
World J Gastroenterol; 2005 Jul; 11(25):3915-9. PubMed ID: 15991293
[TBL] [Abstract][Full Text] [Related]
16. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
[TBL] [Abstract][Full Text] [Related]
17. Utilization of invariant natural killer T cells for gastric cancer treatment.
Xu Q; Li J; Zhang N; Zhang L; Qian R
Future Oncol; 2018 Aug; 14(20):2053-2066. PubMed ID: 30051730
[TBL] [Abstract][Full Text] [Related]
18. Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.
Nowak M; Arredouani MS; Tun-Kyi A; Schmidt-Wolf I; Sanda MG; Balk SP; Exley MA
PLoS One; 2010 Jun; 5(6):e11311. PubMed ID: 20593019
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Output of Adipocyte-iNKT Cell Interplay Is Skewed by a Lipid-Rich Microenvironment.
van Eijkeren RJ; Morris I; Borgman A; Markovska A; Kalkhoven E
Front Endocrinol (Lausanne); 2020; 11():479. PubMed ID: 32849273
[TBL] [Abstract][Full Text] [Related]
20. Histamine receptor 2 modifies iNKT cell activity within the inflamed lung.
Ferstl R; Frei R; Barcik W; Schiavi E; Wanke K; Ziegler M; Rodriguez-Perez N; Groeger D; Konieczna P; Zeiter S; Nehrbass D; Lauener R; Akdis CA; O'Mahony L
Allergy; 2017 Dec; 72(12):1925-1935. PubMed ID: 28618071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
